CANCER RESEARCH AND TREATMENT (CRT) Original Article Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection Xiaoting Song, MD1,2*, Ailu Wu, MD1,3*, Zhixiao Ding, MD2*, Shixiong Liang, PhD1, Chunyan Zhang, PhD1 1Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China, 2People’s Hospital of Wudi County, Binzhou, China, 3The Affiliated Yantai Yuhuangding Hospital of Qingdao University Institution, Yantai, China *Xiaoting Song, Ailu Wu and Zhixiao Ding contributed equally to this work. Article Running Title: Soluble Axl is a diagnostic biomarker of HCC Correspondence: Chunyan Zhang, PhD Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, China Tel: 86-0771-5776046 Fax: 86-0771-5312000 E-mail:
[email protected] Co-correspondence: Shixiong Liang, PhD Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, China Tel: 86-0771Accepted-5335671 Fax: 86-0771-5312000 E-mail:
[email protected] This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi:10.4143/crt.2019.749 1 Korean Cancer Association This article is protected by copyright. All rights reserved. CANCER RESEARCH AND TREATMENT (CRT) Abstract Purpose The purpose of this study was to evaluate the diagnostic value of soluble Axl (sAxl) in hepatocellular carcinoma (HCC) in comparison with serum α-fetoprotein (AFP). Materials and Methods Eighty HCC patients, 80 liver cirrhosis patients (LC), 80 patients with hepatitis B virus (HBV) infection, and 80 healthy controls (HC) were enrolled.